Lanean...
Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents
Therapeutic targeting of the CD40 pathway may be efficacious for cancer treatment. Accumulating evidence suggests synergistic and unique antitumor responses may be achieved using CD40-based therapies in combination with other immunomodulators or targeted agents.
Gorde:
| Argitaratua izan da: | Oncoimmunology |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4292511/ https://ncbi.nlm.nih.gov/pubmed/25610748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21624011.2014.954483 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|